therapeutics

Discover how afucosylated antibodies enhance ADCC by increasing FcγRIIIa binding affinity, with clinical examples and applications in oncology and autoimmune disease therapy.

Intravenous immunoglobulins (IVIGs) offer a versatile treatment modality for a variety of immune-mediated disorders. Originally used for antibody replacement therapy, their unexpected anti-inflammatory and immunomodulatory effects have allowed them to extend their use to

ADCs rely on diverse payloads. Biointron explores cytotoxic drugs and novel mechanisms that expand antibody-drug conjugate applications in oncology and beyond.

Multi-payload ADCs bring new strength to cancer therapy. Biointron explains how combining payloads boosts potency, reduces resistance, and improves patient outcomes.

Antibody drugs in ophthalmology represent a significant advancement in treating various eye diseases. These biologics target specific proteins involved in pathological processes, such as vascular endothelial growth factor (VEGF), which plays a key role in conditions like age-related macular degenera

Antibody-drug conjugates (ADCs) are made up of a monoclonal antibody linked to a cytotoxic drug (payload) through a stable chemical linker, enabling targeted delivery of the drug to specific cancer cells. The ideal ADC payload should have sufficient toxicity, low immunogenicity, high stability, and

Antibody-antibiotic conjugates fight resistant bacteria with precision. Biointron highlights how AACs combine antibody targeting with antibiotic power for infections.

Ozempic, a brand name for the drug semaglutide, was originally developed to manage type 2 diabetes by improving blood sugar control. As a GLP-1 receptor agonist, it mimics a hormone that regulates glucose metabolism and appetite. Beyond its success in diabetes treatment, Ozempic has garnered signifi

ADCs for ES-SCLC. Image credit: DOI: 10.3390/genes15060701Extensive-stage small-cell lung cancer (ES-SCLC) is a particularly aggressive form of lung cancer characterized by rapid growth and early metastasis. Antibody drugs, especially immune checkpoint inhibitors, have emerged as a promising treatme

Antibody therapeutics revolutionize oncology. Biointron highlights checkpoint inhibitors, targeted antibodies, and strategies advancing cancer treatment.

Learn how vaccines trigger antibody production, the immune mechanisms behind protection, different vaccine types, and key factors influencing efficacy and long-term immunity.

Image credit: DOI: 10.1038/s41577-021-00542-xThe progress of COVID-19 therapies has seen remarkable strides, particularly in the development and application of antibody-based treatments. Early in the pandemic, the focus was on supportive care, but the rapid advancement in antibody therapies has sign

Muronomab (Orthoclone OKT3) made history as the first FDA-approved monoclonal antibody. Biointron reviews its impact on immunotherapy and antibody drug development.

Discover highlights from Biointron’s Lunch & Learn with MassBio, featuring HTP antibody platforms, alpaca VHH discovery, bispecific antibodies, and ADC development.

DOI:10.1126/science.adg0564 B cells, or B lymphocytes, are a crucial component of the adaptive immune system andhumoral immunity. They originate from the bone marrow and mature in secondary lymphoid organs, such as the spleen and lymph nodes. The B ce